Head of DMPK
Shape the future of personalised therapeutic solutions by developing field-leading oral macrocycle design
Backed by leading life sciences investors such as Novo Holdings and Forbion, Orbis is empowered to invest in groundbreaking technologies like the field-leading oral macrocycle design and development platform, nGen. Orbis Medicines operates at the intersection of science and technology, integrating cutting-edge tools like artificial intelligence (AI) and machine learning (ML) to accelerate the drug discovery process.
With established facilities and highly skilled professionals in Lausanne, Switzerland, Orbis Medicines is establishing discovery capabilities at a new Copenhagen site. The site is expected to house a team of 15 experienced professionals, bringing the total workforce to 30, including the Lausanne site.
As Head of DMPK at Orbis Medicines, you will report directly to the CDO, and be responsible for building the DMPK department and setting the vision and scientific strategy for DMPK/ADME.
Your main tasks are:
- Establish an in vitro screening platform applicable to the nCycles.
- Establish a pre-formulation screening platform.
- Design PK studies and provide PK (and PK/PD) modelling.
- Establish a drug metabolism/MetID expertise.
- Target assessment from a PK/PD perspective.
- Provide scientific guidance on design drivers for oral macrocycle discovery.
- Provide scientific DMPK leadership and strategic direction to research project teams.
To succeed in the position, your qualifications are a PhD in a related scientific field and 7-10 years of industry experience in peptide Drug Discovery DMPK. Moreover, you have a proven track record of leading DMPK teams (line function or project team) and hands-on experience in drug metabolism, pharmacokinetics (in vitro and in vivo studies), and human PK and DDI predictions.
You are a person with strong communicative skills who thrives in an entrepreneurial start-up environment. You possess strong leadership skills and can guide and motivate the people around you, fostering good collaboration and an inspiring work environment. You are quick to adapt to changes and like to set directions.
Orbis Medicines offers a unique opening to join a growing start-up and opportunities to grow in an innovative, collaborative, and passionate environment that will pioneer a new era for oral macrocycle drug discovery.
Travelling: Limited.
Domicile: Orbis Medicines’ facility in Copenhagen.
At Unique Human Capital, we are committed to promoting diversity and including all perspectives. Thus, we encourage all qualified candidates to apply for the position. All applications must be in English and are treated confidentially.
Orbis Medicines is a biotechnology company focused on pioneering a new oral macrocycle drug discovery era. Macrocycles are a large and diverse family of compounds with highly desirable therapeutic properties. The Orbis nGen platform is designed to systematically explore the macrocycle chemical space using a highly automated chemistry platform and deliver oral macrocycle drug candidates – nCycles – suitable for intra- and extracellular targets. Orbis’ programs are focused on high-value oral alternatives to blockbuster biologic drugs and targets challenging for established modalities. Orbis Medicines was founded by Novo Holdings.
Read more at http://www.orbismedicines.com.
Do you have any questions about the position?
Then feel free to contact the following people directly. All applications must be in English and are treated confidentially.
Gert Vium Andersen, Director Life Sciences
